Filtered By:
Drug: Fortamet
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma
Endocrinology. 2023 Sep 20:bqad139. doi: 10.1210/endocr/bqad139. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is one of the most common malignancies with high mortality, posing a great threat to both human physical and mental health. With the advancement of scientific research, a variety of cancer therapies have been used for OSCC treatment. However, the prognosis of OSCC shows no significant improvement. Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression. Metformin can...
Source: Endocrinology - September 22, 2023 Category: Endocrinology Authors: Jiayi Liu Jing Zhao Xue Qiao Source Type: research
Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial
Conclusion: The use of metformin in breast cancer patients offered a marked protection against paclitaxel-induced PN, which translated to better patient QoL. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05351021, identifier NCT05351021.PMID:37583905 | PMC:PMC10424931 | DOI:10.3389/fphar.2023.1181312
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Hala M Bakry Noha O Mansour Tawfik R ElKhodary Moetaza M Soliman Source Type: research
The metformin immunoregulatory actions in tumor suppression and normal tissues protection
Curr Med Chem. 2023 Jul 3. doi: 10.2174/0929867331666230703143907. Online ahead of print.ABSTRACTThe immune system is the key player in a wide range of responses in normal tissues and tumors to anticancer therapy. Inflammatory and fibrotic responses in normal tissues are the main limitations of chemotherapy, radiotherapy, and also some newer anticancer drugs such as immune checkpoint inhibitors (ICIs). Immune system responses within solid tumors including anti-tumor and tumor-promoting responses can suppress or help tumor growth. Thus, modulation of immune cells and their secretions such as cytokines, growth factors and ep...
Source: Current Medicinal Chemistry - July 5, 2023 Category: Chemistry Authors: Jitendra Gupta Abduladheem Turki Jalil Zahraa Hamzaa Abd Alzahraa Zafar Aminov Fahad Alsaikhan Andr és Alexis Ramírez-Coronel Pushpamala Ramaiah Masoud Najafi Source Type: research
New insight in urological cancer therapy: From epithelial-mesenchymal transition (EMT) to application of nano-biomaterials
Environ Res. 2023 Mar 9:115672. doi: 10.1016/j.envres.2023.115672. Online ahead of print.ABSTRACTA high number of cancer-related deaths (up to 90) are due to metastasis and simple definition of metastasis is new colony formation of tumor cells in a secondary site. In tumor cells, epithelial-mesenchymal transition (EMT) stimulates metastasis and invasion, and it is a common characteristic of malignant tumors. Prostate cancer, bladder cancer and renal cancer are three main types of urological tumors that their malignant and aggressive behaviors are due to abnormal proliferation and metastasis. EMT has been well-documented as...
Source: Environmental Research - March 11, 2023 Category: Environmental Health Authors: Peng He Qiang Dai Xiaojun Wu Source Type: research
Fight Aging! Newsletter, January 9th 2023
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 8, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, November 14th 2022
In this study, we show that TXNIP is vital for the cell fate choice when cells are challenged by various stress signals. Furthermore, prolonged IGF1 treatment leads to the establishment of a premature senescence phenotype characterized by a unique senescence network signature. Combined IGF1/TXNIP-induced premature senescence can be associated with a typical secretory inflammatory phenotype that is mediated by STAT3/IL-1A signaling. Finally, these mechanistic insights might help with the understanding of basic aspects of IGF1-related pathologies in the clinical setting.
Investigating the Ability of Type 2 Diabetes...
Source: Fight Aging! - November 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy
Ann Surg Oncol. 2022 Oct 12. doi: 10.1245/s10434-022-12627-5. Online ahead of print.NO ABSTRACTPMID:36224510 | DOI:10.1245/s10434-022-12627-5
Source: Ann Oncol - October 12, 2022 Category: Cancer & Oncology Authors: Lauren M Postlewait Source Type: research
The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors
Cell Mol Biol Lett. 2022 Jul 22;27(1):58. doi: 10.1186/s11658-022-00356-2.ABSTRACTTumor-infiltrated lymphocytes are exposed to many toxic metabolites and molecules in the tumor microenvironment (TME) that suppress their anti-tumor activity. Toxic metabolites, such as lactate and ketone bodies, are produced mainly by catabolic cancer-associated fibroblasts (CAFs) to feed anabolic cancer cells. These catabolic and anabolic cells make a metabolic compartment through which high-energy metabolites like lactate can be transferred via the monocarboxylate transporter channel 4. Moreover, a decrease in molecules, including caveolin...
Source: Cellular and Molecular Biology Letters - July 22, 2022 Category: Biochemistry Authors: Samaneh Mostafavi Hamidreza Zalpoor Zuhair Mohammad Hassan Source Type: research
Mechanisms of cancer cell killing by metformin: a review on different cell death pathways
Mol Cell Biochem. 2022 Jun 30. doi: 10.1007/s11010-022-04502-4. Online ahead of print.ABSTRACTCancer resistance to anti-tumour agents has been one of the serious challenges in different types of cancer treatment. Usually, an increase in the cell death markers can predict a higher rate of survival among patients diagnosed with cancer. By increasing the regulation of survival genes, cancer cells can display a higher resistance to therapy through the suppression of anti-tumour immunity and inhibition of cell death signalling pathways. Administration of certain adjuvants may be useful in order to increase the therapeutic effic...
Source: Molecular and Cellular Biochemistry - June 30, 2022 Category: Biochemistry Authors: Xiao-Yu Wu Wen-Wen Xu Xiang-Kun Huan Guan-Nan Wu Gang Li Yu-Hong Zhou Masoud Najafi Source Type: research
